
|Videos|October 8, 2021
New Data Surrounding Pediatric Pneumococcal Disease Shows Promise
Musey discussed the highlights of the new data and how these 2 studies are different than previous studies in this topic area.
Advertisement
Pharmacy Times spoke with Luwy Musey, executive director in biologics and vaccines clinical research at Merck, about the results from two phase 3 pediatric studies surrounding pneumococcal disease that was presented at the IDWeek 2021 conference.
Musey discussed the highlights of the new data and how these 2 studies are different than previous studies in this topic area.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
2
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
3
From Underdiagnosed to Under Control: Plozasiran and Pharmacists’ Role in FCS
4
FDA Grants Orphan Drug Designation to Zavabresib for the Treatment of Myelofibrosis
5





















